On April 27, 2026 local time, AstraZeneca officially announced that Saphnelo (Anifrolumab subcutaneous injection) has been approved by the U.S. FDA for patient self-administration via a once-weekly auto-injector, to be used in addition to standard therapy for adult patients with systemic lupus erythematosus (SLE).

The news quickly attracted widespread attention across the global autoimmune disease field.

As one of the most important innovative therapies for systemic lupus erythematosus (SLE) in recent years, the approval of this new subcutaneous self-injection option for Saphnelo not only represents a major upgrade in treatment convenience, but also signals that long-term SLE management is gradually entering a new era of home-based, convenient, and chronic disease-oriented care.

---

The Need for Long-Term SLE Treatment Is Driving Changes in Drug Administration

Systemic lupus erythematosus (SLE) is a complex chronic autoimmune disease that can affect multiple organs, including the skin, joints, kidneys, nervous system, and blood system.

Because the disease tends to relapse repeatedly, many patients require long-term or even lifelong treatment.

For many years, SLE patients receiving biologic therapies have typically needed repeated hospital visits for intravenous infusions.

For some patients, long-term infusions are not only time-consuming but also increase the overall treatment burden.

Traditional intravenous infusion often requires:

• Hospital appointments
• Outpatient waiting time
• Intravenous access establishment
• Infusion monitoring
• Extended hospital stays

Especially for:

• Young female patients
• Busy working individuals
• Patients requiring long-term maintenance therapy
• Patients living in remote areas

Treatment convenience has become an important factor affecting long-term adherence.

The FDA approval of the Saphnelo auto-injector means that patients may soon be able to complete treatment at home, significantly reducing the need for hospital infusions.

---

What Is Saphnelo?

Saphnelo (Anifrolumab) is a monoclonal antibody targeting the type I interferon receptor.

Research has shown that the type I interferon pathway plays a key role in the pathogenesis of systemic lupus erythematosus.

Some SLE patients exhibit abnormally activated interferon signaling, which continuously drives immune dysregulation and inflammatory responses.

The main mechanisms of Saphnelo include:

• Blocking the type I interferon receptor
• Suppressing abnormal immune activation
• Reducing inflammatory responses
• Improving disease activity

Previously, Saphnelo had already been approved in multiple countries and regions as an intravenous infusion therapy for adults with moderate to severe systemic lupus erythematosus.

The newly FDA-approved version is:

A subcutaneous auto-injector self-administration option.

---

What Does the Approval of the Auto-Injector Mean?

Compared with traditional intravenous infusion, the biggest highlight of this approval is that patients can now administer subcutaneous injections once weekly using an auto-injector.

This change is more than simply switching the administration route — it reflects an evolution in SLE treatment models.

Compared with traditional infusion therapy, the auto-injector offers several clear advantages:

Comparison Item	Intravenous Infusion	Auto-Injector
Administration Location	Hospital	Home
Administration Method	Intravenous infusion	Subcutaneous injection
Requires Healthcare Staff	Yes	Self-administration possible
Time Spent in Hospital	Longer	Shorter
Long-Term Convenience	Moderate	Higher
Patient Adherence	Moderate	More patient-friendly

Industry experts believe that this “home self-administration” model may become an important future trend in chronic autoimmune disease treatment.

---

Why Is “Home-Based Treatment” Becoming Increasingly Important?

In recent years, global innovative drug development has gradually shifted from focusing solely on:

“Efficacy”

toward:

“Efficacy + Patient Experience + Long-Term Management.”

Especially in autoimmune diseases, where patients often require long-term maintenance therapy, factors such as:

• Administration convenience
• Long-term adherence
• Treatment experience
• Healthcare resource efficiency

have become key industry priorities.

Currently, therapies including:

• TNF-α inhibitors
• IL-17 inhibitors
• JAK inhibitors
• B-cell targeted therapies

are continuously advancing toward:

• Subcutaneous formulations
• Long-acting formulations
• Auto-injection devices
• Home-based administration models

The FDA approval of the Saphnelo auto-injector further reflects this global trend.

---

The Auto-Injector Era Is Changing Autoimmune Disease Treatment Logic

In the past, many biologic therapies heavily relied on hospital infusion centers.

However, as auto-injection technologies continue to mature, more patients are increasingly seeking:

• More flexible treatment schedules
• Fewer hospital visits
• Lower infusion burden
• Better quality of life

Especially as chronic disease management concepts continue to strengthen, “home-based treatment” is becoming an important direction for the global pharmaceutical industry.

Industry experts believe that future competition in autoimmune disease treatment may not be limited to drug efficacy alone, but may also include:

• Administration methods
• Treatment efficiency
• Long-term treatment experience
• Patient management capabilities

The growing adoption of auto-injectors may also further promote digital follow-up systems and remote chronic disease management.

---

Summary

The official FDA approval of the Saphnelo (Anifrolumab subcutaneous injection) auto-injector represents not only an important new advancement in systemic lupus erythematosus (SLE) treatment, but also a broader upgrade in long-term autoimmune disease management models.

Compared with traditional intravenous infusions, auto-injectors can significantly improve treatment convenience and may help enhance long-term adherence and patient quality of life.

As more subcutaneous and home-administered innovative therapies continue to emerge, SLE patients may gradually move away from the era of prolonged infusion treatments and enter a more convenient, efficient, and patient-friendly phase of chronic disease management.

Hong Kong Dengyue Pharma has established partnerships with more than 30 international pharmaceutical companies across Europe, the United States, and Japan, providing original innovative therapies for autoimmune diseases, including advanced drug delivery formats such as subcutaneous injections and auto-injectors, helping patients better adapt to home-based treatment scenarios.